<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411329</url>
  </required_header>
  <id_info>
    <org_study_id>R15/2020</org_study_id>
    <nct_id>NCT04411329</nct_id>
  </id_info>
  <brief_title>Caudal Epidural With Non Opioid Adjuvants in Lumbosacral Spine Surgery</brief_title>
  <official_title>Caudal Epidural With Non Opioid Adjuvants in Lumbosacral Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lumbosacral spine surgeries are accompanied with severe postoperative pain which has a&#xD;
      negative effect on patients' recovery. Preemptive analgesia before lumbosacral spine&#xD;
      surgeries should be implemented to prevent CNS plasticity and to provide effective pain&#xD;
      relief.&#xD;
&#xD;
      The most common way to provide pain management after spine surgery is the intravenous&#xD;
      analgesia. Caudal epidural analgesia can be a highly effective method for postoperative pain&#xD;
      relief.&#xD;
&#xD;
      The most common way to provide pain management after spine surgery is the intravenous&#xD;
      analgesia. Caudal epidural analgesia can be a highly effective method for postoperative pain&#xD;
      relief. acting drugs last from 4-8 hours,But this can be prolonged by adding non opioid&#xD;
      adjuvants like steroid( dexamethazone,betamethasone), alpha2 agonists (clonidine,&#xD;
      dexmedetomidine), or their combination. This study will compare adding different non opioid&#xD;
      adjuvants to bupivacaine in caudal epidural for preventive analgesia in lumbosacral spine&#xD;
      surgery which can be a part of multimodal analgesia protocol.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patient will be enrolled in the study. They will be allocated randomly into 3 groups.&#xD;
      after induction of general anesthesia and changing the patient into prone position injection&#xD;
      of the study cocktail through caudal epidural route.(20 ml before skin incision and 10 ml of&#xD;
      the same mixture at the end of surgery) in all patients.&#xD;
&#xD;
      In the first group patients will receive 0.125% bupivacaine with 8 mg dexamethasone In the&#xD;
      second group we will add 50µg dexmedetomidine to the previous mixture given to the first&#xD;
      group.&#xD;
&#xD;
      In the third group we will add 1500 IU hyalurodinase to the mixture given to the first group&#xD;
&#xD;
      During the operation adjustment of sevoflurane concentration and fentanyl incremental doses&#xD;
      (0.5 μg/kg) will be according to hemodynamic measurements.&#xD;
&#xD;
      Clinical signs of inadequate analgesia is defined as an increase in blood pressure and heart&#xD;
      rate more than 20% from baseline. Efficacy of the caudal epidural block will be tested at&#xD;
      beginning of skin incision (15-20 minutes after block). If signs of inadequate analgesia are&#xD;
      observed, fentanyl 0.5 µg/kg will be given and those patients will be excluded from the&#xD;
      study.&#xD;
&#xD;
      In case of decrease in Blood Pressure greater than 20% from baseline, the patient will be&#xD;
      infused by 500 ml ringer lactate and if blood pressure is not responding, administration of&#xD;
      increments of 3 mg ephedrine will be given. Also If heart rate decreased to 45 beats/min,&#xD;
      atropine sulfate 0.01 mg/kg will be given. Muscle paralysis will be antagonized by sugmmadex&#xD;
      2mg/kg at the end of surgery after switching the patient to the supine position.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2020</start_date>
  <completion_date type="Actual">May 6, 2021</completion_date>
  <primary_completion_date type="Actual">May 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The duration of analgesia</measure>
    <time_frame>postoerative 24 hours.</time_frame>
    <description>time from second dose caudal epidural block to first analgesic requirement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>VAS score from zero for (no pain) till 10 for ( the most severe intractable pain)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Caudal Analgesia for Lumosacral Spine Surgeries</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 30 ml of 0.125% bupivacaine with 8 mg dexamethasone (20 ml before skin incision and 10 ml at end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>we will add 50µg dexmedetomidine to the previous mixture given to group A (20 ml before skin incision and 10 ml at end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>we will add 1500 IU hyalurodinase to the mixture given to group A. (20 ml before skin incision and 10 ml at end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>local anesthetics, steriod, alpha 2 blockers</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <arm_group_label>group c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>dexamethazone</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <arm_group_label>group c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>dexmedetomidine</description>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyalouridinase</intervention_name>
    <description>hyalouridinase</description>
    <arm_group_label>group c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are aged from 18-65 years , ASA I and II, scheduled for lumbar spine surgery&#xD;
             (laminectomy, discectomy, foraminotomy, fenestration or fusion) in a virgin back.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with multiple level fixation, revision surgery, complicated spinal canal&#xD;
             stenosis, traumatic lumbar surgeries were excluded, patients with addiction, allergy&#xD;
             to local anesthetics or to any drug used in the study and those with coagulation&#xD;
             abnormality are also excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanaa Farag Mahmoud</name>
      <address>
        <city>Cairo</city>
        <state>New Cairo</state>
        <zip>11835</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ainshams hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Solanki SL, Bharti N, Batra YK, Jain A, Kumar P, Nikhar SA. The analgesic effect of intrathecal dexmedetomidine or clonidine, with bupivacaine, in trauma patients undergoing lower limb surgery: a randomised, double-blind study. Anaesth Intensive Care. 2013 Jan;41(1):51-6.</citation>
    <PMID>23362890</PMID>
  </reference>
  <reference>
    <citation>Barham G, Hilton A. Caudal epidurals: the accuracy of blind needle placement and the value of a confirmatory epidurogram. Eur Spine J. 2010 Sep;19(9):1479-83. doi: 10.1007/s00586-010-1469-8. Epub 2010 May 29.</citation>
    <PMID>20512512</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 16, 2021</last_update_submitted>
  <last_update_submitted_qc>May 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sanaa Farag Mahmoud Wasfy</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

